Definium Therapeutics, Inc. (DFTX)
Definium Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in New York, NY, US. The stock last traded at $38.09, up 0.24% on the session, giving a market capitalisation of $5.06B. On trailing twelve-month figures it carries a trailing P/E of -11.07, a net margin of 0.0%. Its beta of 2.26 implies it has historically moved more than the broad market.
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Definium Therapeutics, Inc. is most often compared with the following Healthcare names: